Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study.

Glorieux FH, Langdahl B, Chapurlat R, De Beur SJ, Sutton VR, Poole KES, Dahir KM, Orwoll ES, Willie BM, Mikolajewicz N, Zimmermann E, Hosseinitabatabaei S, Ominsky MS, Saville C, Clancy J, MacKinnon A, Mistry A, Javaid MK

Open source

DOI: 10.1093/jbmr/zjae112
Published: 2024 Sep 2
Container: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/jbmr/zjae112,
  title = {Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study.},
  author = {Glorieux FH and Langdahl B and Chapurlat R and De Beur SJ and Sutton VR and Poole KES and Dahir KM and Orwoll ES and Willie BM and Mikolajewicz N and Zimmermann E and Hosseinitabatabaei S and Ominsky MS and Saville C and Clancy J and MacKinnon A and Mistry A and Javaid MK},
  year = {2024},
  journal = {Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research},
  doi = {10.1093/jbmr/zjae112},
  url = {https://doi.org/10.1093/jbmr/zjae112}
}

RIS

TY  - JOUR
TI  - Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study.
AU  - Glorieux FH
AU  - Langdahl B
AU  - Chapurlat R
AU  - De Beur SJ
AU  - Sutton VR
AU  - Poole KES
AU  - Dahir KM
AU  - Orwoll ES
AU  - Willie BM
AU  - Mikolajewicz N
AU  - Zimmermann E
AU  - Hosseinitabatabaei S
AU  - Ominsky MS
AU  - Saville C
AU  - Clancy J
AU  - MacKinnon A
AU  - Mistry A
AU  - Javaid MK
PY  - 2024
JO  - Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
DO  - 10.1093/jbmr/zjae112
UR  - https://doi.org/10.1093/jbmr/zjae112
ER  -

APA

FH, G., B, L., R, C., SJ, D. B., VR, S., KES, P., KM, D., ES, O., BM, W., N, M., E, Z., S, H., MS, O., C, S., J, C., A, M., A, M., & MK, J. (2024). Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study.. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. https://doi.org/10.1093/jbmr/zjae112

Source records

pubmed · retrieved 2026-09-26T07:27:36.295Z